Oncology

McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (NYSE: MCK) is ending 2025 as one of the standout performers in U.S. healthcare — but as of Wednesday, December 3, its stock is taking a breather. At the close, McKesson shares finished at $805.37, down 2.93% on

4 December 2025

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc (LON:GSK, NYSE:GSK) finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop. Key takeaways

20 November 2025

Analyst Ratings · Oncology · Pharma News · Share Prices · Stock Market

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in

17 November 2025

Cancer Research · Clinical Trials · Healthcare News · Oncology · Pharmaceuticals

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on

17 November 2025

Biotech Industry · Mergers & Acquisitions · NASDAQ:CDTX · NYSE:JNJ · NYSE:MRK · NYSE:PFE · Oncology · Patent News · Pharmaceuticals

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs

11 November 2025

Business News · Mergers & Acquisitions · NYSE:MRK · NYSE:NVO · NYSE:PFE · Oncology · Pharmaceuticals · Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)

10 November 2025

Biotechnology · Clinical Trials · NASDAQ:COGT · Oncology · Pharmaceutical News · Stock Market

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

In April 2025, Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation. The device pairs an immunohistochemistry stain for TROP2 with a digital pathology AI algorithm that runs in Roche’s Navify system

17 July 2025

AI in Healthcare · FDA Approvals · Medical Diagnostics · NYSE:AZN · NYSE:RHHBY · Oncology · Technological Innovation

Oncology News 17 July 2025 - 4 December 2025